Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom P Freeman

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 23, 2025
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trialEdward Chesney, Dominic Oliver, Ananya Sarma, et al.
Psychopharmacology|April 21, 2022
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyMichael A P Bloomfield, Yumeya Yamamori, Chandni Hindocha, et al.
Psychological Medicine|August 8, 2025
The impact of childhood trauma and cannabis use on paranoia: a structural equation model approachGiulia Trotta, Edoardo Spinazzola, Hannah Degen, et al.
Addiction (Abingdon, England)|March 19, 2026
Associations of cannabis use, tobacco use and co-use with brain volume: A systematic review and meta-analysisKatherine Sawyer, Tom P Freeman, Martine Skumlien, et al.
Psychopharmacology|May 7, 2026
A mindfulness-based intervention to reduce altered brain reward function in cannabis use disorder: a double-blind, active and passive, randomised controlled fMRI trialEmillie Beyer, Martine Skumlien, Govinda Poudel, et al.
Neuroscience and Biobehavioral Reviews|June 4, 2026
The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regressionIsabella Goodwin, Dominic Oliver, Edward Chesney, et al.
The Lancet. Psychiatry|August 1, 2020
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trialTom P Freeman, Chandni Hindocha, Gianluca Baio, et al.
Comprehensive Psychiatry|January 15, 2026
Attentional bias in people with moderate-to-severe cannabis use disorderMarianna Quinones-Valera, Gary Chan, Madeleine I Fraser, et al.
Addiction (Abingdon, England)|June 27, 2025
Synthetic cannabinoids in e-cigarettes seized from English schoolsGyles E Cozier, Matthew Gardner, Sam Craft, et al.
The FEBS Journal|January 28, 2023
Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitorsSarah A Hindson, Rachael C Andrews, Michael J Danson, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 23, 2025
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trialEdward Chesney, Dominic Oliver, Ananya Sarma, et al.
Psychopharmacology|April 21, 2022
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyMichael A P Bloomfield, Yumeya Yamamori, Chandni Hindocha, et al.
Psychological Medicine|August 8, 2025
The impact of childhood trauma and cannabis use on paranoia: a structural equation model approachGiulia Trotta, Edoardo Spinazzola, Hannah Degen, et al.
Addiction (Abingdon, England)|March 19, 2026
Associations of cannabis use, tobacco use and co-use with brain volume: A systematic review and meta-analysisKatherine Sawyer, Tom P Freeman, Martine Skumlien, et al.
Psychopharmacology|May 7, 2026
A mindfulness-based intervention to reduce altered brain reward function in cannabis use disorder: a double-blind, active and passive, randomised controlled fMRI trialEmillie Beyer, Martine Skumlien, Govinda Poudel, et al.
Neuroscience and Biobehavioral Reviews|June 4, 2026
The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regressionIsabella Goodwin, Dominic Oliver, Edward Chesney, et al.
The Lancet. Psychiatry|August 1, 2020
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trialTom P Freeman, Chandni Hindocha, Gianluca Baio, et al.
Comprehensive Psychiatry|January 15, 2026
Attentional bias in people with moderate-to-severe cannabis use disorderMarianna Quinones-Valera, Gary Chan, Madeleine I Fraser, et al.
Addiction (Abingdon, England)|June 27, 2025
Synthetic cannabinoids in e-cigarettes seized from English schoolsGyles E Cozier, Matthew Gardner, Sam Craft, et al.
The FEBS Journal|January 28, 2023
Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitorsSarah A Hindson, Rachael C Andrews, Michael J Danson, et al.
Pageof 20